Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

AISAP, an Israeli healthcare technology company focused on using artificial intelligence (AI) to enhance medical imaging results, has gained U.S. Food and Drug Administration (FDA) clearance for its new point-of-care ultrasound (POCUS) software platform, AISAP Cardio.

FDA clears AI-powered POCUS platform for structural heart disease, heart failure

The cloud-based platform was designed to help even inexperienced users scan and diagnose a majority of common heart issues within minutes without leaving the patient’s side.

AI cardiology heart artificial intelligence deep learning

FDA approves new AI-powered imaging software from Nanox subsidiary

According to Nanox.AI, previously known as Zebra Medical Vision, the updated software helps "bridge the divide between radiology and cardiology."

Images coronary calcium imaging by optical coherence tomography (OCT) and high-definition intravascular ultrasound (IVUS).

OCT-guided PCI improves survival after life-threatening heart attacks

Researchers explored data from nearly 4,000 STEMI patients, noting that optical coherence tomography may be a valuable first step of any treatment strategy. 

Ron Blankstein, MD, FACC, FASNC, MSCCT, FASPC, associate director, cardiovascular imaging program, director, cardiac computed tomography, Brigham and Women’s Hospital, and a professor of medicine and radiology, Harvard Medical School, explains a few of the recent advancements in cardiac MRI, nuclear imaging and computed tomography.

Exploring major breakthroughs in cardiac imaging

Ron Blankstein, MD, director of cardiac computed tomography for Brigham and Women’s Hospital, details recent developments in cardiac MRI, nuclear imaging and CT.

Siemens Healthineers has gained U.S. Food and Drug Administration (FDA) clearance for Acuson Origin, its new cardiovascular ultrasound system featuring advanced artificial intelligence (AI) capabilities. The Acuson Origin represents a significant update from the prior Siemens Healthineers cardiovascular ultrasound system, the Acuson SC2000.

Siemens Healthineers gains FDA clearance for new AI-powered cardiovascular ultrasound system

The Acuson Origin system includes advanced AI algorithms designed to assist users with the treatment of diagnostic, structural heart, vascular, electrophysiological and pediatric patients. It also comes packaged with a new 4D ICE catheter capable of multiplanar reconstruction imaging with or without the use of an electrocardiogram.

CMR of a patient showing evidence of myocardial hypertrophy

MRI results help cardiologists predict heart failure risk

"This breakthrough suggests that heart MRI could potentially replace invasive diagnostic tests," one specialist said. 

CMS may double Medicare payments for cardiac CT

The agency is gathering feedback on a proposal to double the amount hospitals are paid for coronary computed tomography angiography, with the comment period ending Sept. 9.

artificial intelligence consultation

Generative AI explains echo results to heart patients

Researchers used OpenAI’s ChatGPT technology to build 100 patient-friendly echo reports, evaluating each one for accuracy, relevance and understandability. The AI reports passed the test with flying colors. 

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.